Skip to main navigation Skip to search Skip to main content

Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors

  • T. J. Powell*
  • , H. Ben-Bassat
  • , B. Y. Klein
  • , H. Chen
  • , N. Shenoy
  • , J. McCollough
  • , B. Narog
  • , A. Gazit
  • , Z. Harzstark
  • , M. Chaouat
  • , R. Levitzki
  • , C. Tang
  • , J. McMahon
  • , L. Shawver
  • , A. Levitzki
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Psoriasis is characterized by hyperproliferation of keratinocytes associated with an inflammatory infiltrate in the epidermis. Among factors which may be related to hyperplasia of psoriatic keratinocytes is the persistent autocrine stimulation of the epidermal growth factor receptor (EGFR) by transforming growth factor-α. Owing to the pivotal role of the EGFR in driving the growth of human psoriatic keratinocytes, we examined two selective inhibitors of EGFR kinase activity: 4-(3-bromophenylamino)-6,7- dimethoxyquinazoline (AG1517/SU5271) and 4-(3-chlorophenylamino)-6,7- dimethoxyquinazoline (AG1478) on psoriatic keratinocytes. SU5271 potently inhibits ligand-induced autophosphorylation of EGFR, and downstream signal transduction events, including DNA replication and cell cycle progression, SU5271, at micromolar concentrations, inhibited the proliferation of keratinocytes isolated from psoriatic lesions in excellent correlation with its EGFR kinase inhibitory activity in these cells. Biologically active concentrations of SU5271 penetrated human cadaver skin, suggesting that this compound is a strong candidate as an antipsoriatic agent.

Original languageEnglish
Pages (from-to)802-810
Number of pages9
JournalBritish Journal of Dermatology
Volume141
Issue number5
DOIs
StatePublished - 1999

Keywords

  • Epidermal growth factor receptor
  • Keratinocytes
  • Psoriasis
  • Quinazolines
  • Tyrosine kinase inhibitors

Fingerprint

Dive into the research topics of 'Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this